The financials
AnaptysBio, Inc. by the numbers
AnaptysBio, Inc. (ANAB) reported revenue of $26M in Q1 2026 (quarter ended March 31, 2026), down 8.0% from the same quarter a year earlier. That came with net loss of $53M. For the full year FY2025, revenue was $235M (+157% year on year) and net income −$13M. Its largest product in 2025-Q3 was Anaptys Bio Generated Anti PD1 Jemperli Dostarlimab at $50M, 100% of the disclosed total, just ahead of Transaction Service at 0.2%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $26M | $28M | −8.0% |
| Operating income | −$35M | −$28M | n/a |
| Net income | −$53M | −$39M | n/a |
| Diluted EPS | −$1.84 | −$1.28 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Anaptys Bio Generated Anti PD1 Jemperli Dostarlimab | $50M | 100% |
| Transaction Service | $100K | 0.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $100.0K (-100%)
Transaction Service grew 0.00% year on yearLicense -100% year on year
Segment Latestquarter on quarteryear on year
- Transaction Service$100.0K$100.0KQoQ -year on year 0.00%-0.00%
- Anaptys Bio Generated Anti PD1 Jemperli Dostarlimab$0.00$0.00QoQ -100%year on year --100%-
- Anaptys Bio Generated Anti TIM3 GSK4069889 A Cobolimab--QoQ -year on year ---
- License$0.00$0.00QoQ -year on year -100%--100%
Biotechnology
Ranks #102 of 145 by Smart Score